...
首页> 外文期刊>Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver >New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases
【24h】

New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases

机译:肠道微生物群的新概念以及不可吸收抗生素的作用及特殊参考消化系统疾病的利福昔林

获取原文
获取原文并翻译 | 示例

摘要

Digestive diseases are a broad range of chronic disorders that substantially and negatively impact the patients' quality of life. Here, we review our current understanding on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease, with a special focus on the gut microbiota composition associated with these disorders. Furthermore, we review the current clinical practice for their therapeutic treatments, including probiotics, diet change, non-adsorbable disaccharides, and antibiotics. We highlight that broad-spectrum non-adsorbable antibiotics, such as rifaximin, are quite effective and safe for the treatment of all essayed digestive diseases. (c) 2018 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
机译:消化系统是一种广泛的慢性疾病,其基本上和对患者的生活质量产生了负面影响。 在这里,我们目前对肝脑病,肠易肠道综合征和憩室病的病理生理学进行了解,特别关注与这些疾病相关的肠道微生物群组合物。 此外,我们审查了目前其治疗治疗的临床实践,包括益生菌,饮食变化,不可吸附的二糖和抗生素。 我们强调,广谱无吸收的抗生素,如利福昔尼蛋白,对治疗所有散文消化疾病是非常有效和安全的。 (c)2018年由elsevier有限公司代表Editrice Gastroenterlologica Italiana S.R.L出版。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号